Compare Freshworks Inc (FRSH) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Illumina, Inc. — how do they compare? Freshworks Inc trades at $11.63 (market cap $3.31B), while Illumina, Inc. trades at $189.95 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 8.8× Freshworks Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | ILMN | |
|---|---|---|
Market Cap | $3.31B | $29.12B |
Sector | Technology | Health |
52-Week High | $13.97 | $205.10 |
52-Week Low | $6.88 | $91.00 |
Enterprise Value | $2.68B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $11.98, up 1.18% with bullish technical signals and strong fundamentals. The company reported Q2 2026 revenue growth of 16% year-over-year, achieving its first GAAP profitability quarter with $3.2 million net income. Recent FedRAMP designation and Gartner leadership recognition highlight strategic progress. Analyst consensus shows 50% buy ratings with a $16.50 price target, suggesting 38% upside potential.
The outlook remains positive with accelerating revenue growth and improved profitability, though elevated P/E and EV/EBITDA ratios warrant caution. Key risks include competitive pressures in SaaS and execution challenges. Current momentum supports continued appreciation toward analyst targets, making FRSH attractive for growth-oriented investors despite valuation concerns.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
